明德生物收盘下跌2.01%，滚动市盈率125.77倍，总市值48.81亿元

Core Viewpoint - Mingde Biological's stock closed at 20.99 yuan, down 2.01%, with a rolling PE ratio of 125.77 times, indicating a significant premium compared to the industry average [1] Company Summary - Mingde Biological focuses on the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - For Q1 2025, the company reported revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, reflecting a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Mingde Biological at the 108th rank within the industry [1] - As of Q1 2025, there are 2 institutional investors holding shares in Mingde Biological, with a total holding of 123,100 shares valued at 0.02 million yuan [1]